These effects may be explained by inhibition of the MAPK pathway given that MEK inhibitors are associated with responses in BRAF WT melanoma 27, 28, and other cell autonomous or cell non‐autonomous mechanisms, which is supported by our biomarker analysis. This evidence concerns the gene MAP2K7 and melanoma.